NCT04319276 is a Phase 1 clinical trial of Gallium maltolate (500 mg) in Glioblastoma, sponsored by Medical College of Wisconsin.

Who is sponsoring NCT04319276?

NCT04319276 is sponsored by Medical College of Wisconsin.

What drugs are being tested in NCT04319276?

Interventions in NCT04319276: Gallium maltolate (500 mg), Gallium maltolate (1,000 mg), Gallium maltolate (1,500 mg), Gallium maltolate (2,000 mg), Gallium maltolate (2,500 mg), Gallium maltolate (recommended phase 2 dose).

What condition does NCT04319276 study?

NCT04319276 studies Glioblastoma.

Is NCT04319276 still recruiting?

NCT04319276 is currently active, enrolled. Last updated 3 November 2025.

Last reviewed 2025-11-03 · How we verify

NCT04319276

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Active, enrolled Phase 1 Last updated 3 November 2025

What this trial tests

Phase 1 trial testing Gallium maltolate (500 mg) in Glioblastoma in 26 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 November 2022

Primary endpoint
13 February 2025

1 March 2027

Quick facts

Lead sponsor	Medical College of Wisconsin
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	26
Start date	11 November 2022
Primary completion	13 February 2025
Estimated completion	1 March 2027
Sites	1 location across United States

Drugs / interventions tested

Gallium maltolate (500 mg) — full drug profile →
Gallium maltolate (1,000 mg)
Gallium maltolate (1,500 mg) — full drug profile →
Gallium maltolate (2,000 mg) — full drug profile →
Gallium maltolate (2,500 mg) — full drug profile →
Gallium maltolate (recommended phase 2 dose) — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Medical College of Wisconsin

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Potent <i>in vivo</i> efficacy of oral gallium maltolate in treatment-resistant glioblastoma.
Al-Gizawiy MM, Wujek RT, Alhajala HS, Cobb JM, et al · · 2023 · cited 4× · PMID 38288102 · DOI 10.3389/fonc.2023.1278157
In Vivo Trafficking of the Anticancer Drug Tris(8-Quinolinolato) Gallium (III) (KP46) by Gallium-68/67 PET/SPECT Imaging.
Darwesh AMF, Imberti C, Bartnicka JJ, Al-Salemee F, et al · · 2023 · cited 4× · PMID 37894695 · DOI 10.3390/molecules28207217
Gallium disrupts endoplasmic reticulum iron metabolism to induce lipid metabolic reprogramming in glioblastoma cells.
Petronek MS, Stolwijk JM, Zaher A, Owusu SB, et al · · 2025 · cited 1× · PMID 40469110 · DOI 10.1016/j.isci.2025.112404
Regulatory networks of iron sulfur cluster biology in cancer mechanisms and therapeutic perspectives.
Yao S, Guan H, Chai J, Liu X. · · 2026 · PMID 41952995 · DOI 10.1016/j.isci.2026.115256

Verify or expand the search:

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Medical College of Wisconsin trials

Trials by the same sponsor.

NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04319276 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
Last refreshed: 3 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04319276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing